J. Mol. Stud. Med. Res. | Volume 06, Issue 01, 193-199 | https://doi.org/10.18801/jmsmr.060121.23
Article type: Research article, Received: 12.07.2021, Revised: 28.11.2021, Date of Publication: 20 December 2021.
Article type: Research article, Received: 12.07.2021, Revised: 28.11.2021, Date of Publication: 20 December 2021.
A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective
Mousumi Baishnab 1 and Titas Roy 2
1Dhaka Medical College, Dhaka-1000, Bangladesh.
2Dept. of Neurosurgery, Faculty of Surgery, Dhaka Medical College Hospital, Dhaka-1000, Bangladesh.
✉ Corresponding author: [email protected] (Baishnab, M.).
1Dhaka Medical College, Dhaka-1000, Bangladesh.
2Dept. of Neurosurgery, Faculty of Surgery, Dhaka Medical College Hospital, Dhaka-1000, Bangladesh.
✉ Corresponding author: [email protected] (Baishnab, M.).
Abstract
Carcinoma cervix is one of the most important preventable and curable diseases of women of reproductive age. Human Papilloma Virus (HPV), especially the oncogenic HPV are the main culprit of this disease. Effective vaccination of HPV can prevent Carcinoma cervix and it is the preferred method for long-term reduction of Cervical neoplasia. Developed countries have established comprehensive HPV vaccination programs, but it is not established in the low-middle income countries yet. The objective of our paper is to evaluate the efficacy and cost-effectiveness of HPV vaccination for the prevention of Ca Cervix and make a comprehensive cancer control plan for Ca Cervix in a low-middle income country setting. We used narrative analysis to evaluate the cost-effectiveness of HPV vaccination for a low resource low-middle income country and propose a comprehensive cancer control plan appropriate for them. Primary prevention (HPV vaccination) along with Secondary prevention (Screening by Visual Inspection with Acetic Acid-VIA or Pap smear or HPV DNA detection) and early treatment of precancerous lesions are very much cost-effective for the prevention of Cervical cancer. Carcinoma cervix is a preventable and curable disease despite rapidly growing cancer with high mortality and morbidity. A comprehensive cancer control plan with effective screening and HPV vaccination will make a difference by reducing the national and global burden of Cervical.
Key Words: Carcinoma Cervix, Human Papilloma Virus, Vaccination and Screening
Carcinoma cervix is one of the most important preventable and curable diseases of women of reproductive age. Human Papilloma Virus (HPV), especially the oncogenic HPV are the main culprit of this disease. Effective vaccination of HPV can prevent Carcinoma cervix and it is the preferred method for long-term reduction of Cervical neoplasia. Developed countries have established comprehensive HPV vaccination programs, but it is not established in the low-middle income countries yet. The objective of our paper is to evaluate the efficacy and cost-effectiveness of HPV vaccination for the prevention of Ca Cervix and make a comprehensive cancer control plan for Ca Cervix in a low-middle income country setting. We used narrative analysis to evaluate the cost-effectiveness of HPV vaccination for a low resource low-middle income country and propose a comprehensive cancer control plan appropriate for them. Primary prevention (HPV vaccination) along with Secondary prevention (Screening by Visual Inspection with Acetic Acid-VIA or Pap smear or HPV DNA detection) and early treatment of precancerous lesions are very much cost-effective for the prevention of Cervical cancer. Carcinoma cervix is a preventable and curable disease despite rapidly growing cancer with high mortality and morbidity. A comprehensive cancer control plan with effective screening and HPV vaccination will make a difference by reducing the national and global burden of Cervical.
Key Words: Carcinoma Cervix, Human Papilloma Virus, Vaccination and Screening
Article Full-Text PDF
| jmsmr_23.01.06.2021_a_comprehensive_cervical_cancer_control_plan_in_a_low-middle_income_country-_bangladesh_perspective.pdf |
Article Metrics
|
Share This Article
|
|
Article Citations
MLA
Baishnab, M. and Roy, T. “A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective”. Journal of Molecular Studies and Medicine Research, 06(01), (2021): 193-199.
APA
Baishnab, M. and Roy, T. (2021). A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Molecular Studies and Medicine Research, 06(01), 193-199.
Chicago
Baishnab, M. and Roy, T. “A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective”. Journal of Molecular Studies and Medicine Research, 06(01), (2021): 193-199.
Harvard
Baishnab, M. and Roy, T. 2021. A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Molecular Studies and Medicine Research, 06(01), pp. 193-199.
Vancouver
Baishnab, M and Roy, T. A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Bioscience and Agriculture Research, 2021 December, 06(01): 193-199.
Baishnab, M. and Roy, T. “A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective”. Journal of Molecular Studies and Medicine Research, 06(01), (2021): 193-199.
APA
Baishnab, M. and Roy, T. (2021). A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Molecular Studies and Medicine Research, 06(01), 193-199.
Chicago
Baishnab, M. and Roy, T. “A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective”. Journal of Molecular Studies and Medicine Research, 06(01), (2021): 193-199.
Harvard
Baishnab, M. and Roy, T. 2021. A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Molecular Studies and Medicine Research, 06(01), pp. 193-199.
Vancouver
Baishnab, M and Roy, T. A comprehensive Cervical Cancer Control Plan in a low-middle income country: Bangladesh perspective. Journal of Bioscience and Agriculture Research, 2021 December, 06(01): 193-199.
References
- Aref-Adib, M. and Freeman-Wang, T. (2016). Cervical cancer prevention and screening: the role of human papillomavirus testing. The Obstetrician & Gynaecologist, 18(4), 251-263. DOI: https://doi.org/10.1111/tog.12279.
- Audisio, R. A. Icardi, G. Isidori, A. M. Liverani, C. A. Lombardi, A. Mariani, L. and Zuccotti, G. V. (2016). Public health value of universal HPV vaccination. Critical Reviews in Oncology/Hematology, 97, 157-167. DOI: https://doi.org/10.1016/j.critrevonc.2015.07.015.
- Brinton, L. A. Herrero, R. Reeves, W. C. de Britton, R. C. Gaitan, E. and Tenorio, F. (1993). Risk factors for cervical cancer by histology. Gynecologic oncology, 51(3), 301-306.
- Brisson, M. and Drolet, M. (2019). Global elimination of cervical cancer as a public health problem. The Lancet Oncology, 20(3), 319-321.
- Cancer, I. A. f. R. o. (2020a). Cervix uteri fact sheet, Globocan 2020. Retrieved from https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf.
- Cancer, I. A. f. R. o. (2020b). GLOBOCAN 2020: New Global Cancer Data. Retrieved from https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
- Canfell, K. (2019). Towards the global elimination of cervical cancer. Papillomavirus research, 8, 100170.
- MAYO Clinic (2021). Cervical Cancer. Retrieved from https://www.mayoclinic.org/diseases-conditions/cervical-cancer/symptoms-causes/syc-20352501.
- Cancer Council (2020). Cervical Screening. Retrieved from https://www.cancer.org.au/cervicalscreening/?gclid=CjwKCAiA17P9BRB2EiwAMvwNyBrqwY8fYQx1pGynOYbOfcE_0IVPlsWA3EoCNoYcB6qdGUud9nHiqxoCTMkQAvD_BwE.
- Cancer Council (2020b). Cervical cancer. Retrieved from https://www.cancer.org.au/cancer-information/types-of-cancer/cervical-cancer.
- Denny, L. (2005). The prevention of cervical cancer in developing countries. BJOG: An International Journal of Obstetrics & Gynaecology, 112(9), 1204-1212.
- Denny, L. Kuhn, L. Pollack, A. and Wright Jr, T. C. (2002). Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer, 94(6), 1699-1707.
- Gallagher, K. E. LaMontagne, D. S. and Watson-Jones, D. (2018). Status of HPV vaccine introduction and barriers to country uptake. Vaccine, 36(32), 4761-4767.
- Huh, W. K. Ault, K. A. Chelmow, D. Davey, D. D. Goulart, R. A. Garcia, F. A. and Saslow, D. (2015). Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol, 25(2), 330-337.
- Hulka, B. S. (1982). Risk factors for cervical cancer. Journal of Chronic Diseases, 35(1), 3-11.
- Islam, J. Y. Khatun, F. Alam, A. Sultana, F. Bhuiyan, A. Alam, N. and Nahar, Q. (2018). Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study. BMC women's health, 18(1), 1-13.
- Mahumud, R. (2019). Bivalent HPV vaccine cost effective at Gavi prices in Bangladesh. Pharmaco Economics & Outcomes News, 841, 4-16.
- Mahumud, R. A. Gow, J. Alam, K. Keramat, S. A. Hossain, M. G. Sultana, M. and Islam, S. M. S. (2020). Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Vaccine, 38(2), 165-172. DOI: https://doi.org/10.1016/j.vaccine.2019.10.037
- WHO (World Health Organization) (2017). National Strategy for Cervical Cancer Prevention and Control in Bangladesh, 2017-2022. Retrieved from https://www.who.int/bangladesh/news/detail/24-09-2017-national-strategy-for-cervical-cancer-prevention-and-control-in-bangladesh-2017-2022
- WHO (World Health Organization) (2020a). Bangladesh Cancer Country Profile 2020. Retrieved from https://www.who.int/cancer/country-profiles/BGD_2020.pdf
- WHO (World Health Organization) (2020b). Cervical Cancer. Retrieved from https://www.who.int/health-topics/cervical-cancer#tab=tab_1.
- WHO (World Health Organization) (2020c). Cervical Cancer Elimination Initiative. Retrieved from https://www.who.int/initiatives/cervical-cancer-elimination-initiative.
- WHO (World Health Organization) (2021). Cancer Fact Sheets. Retrieved from https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Globally%2C%20about%201%20in%206,%2D%20and%20middle%2Dincome%20countries.
- Prevention, C. f. D. C. a. (2021). HPV Vaccine Safety and Effectiveness Data. Retrieved from https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html.
- Schiffman, M. Wentzensen, N. Wacholder, S. Kinney, W. Gage, J. C. and Castle, P. E. (2011). Human papillomavirus testing in the prevention of cervical cancer. Journal of the National cancer institute, 103(5), 368-383.
- Simms, K. T. Steinberg, J. Caruana, M. Smith, M. A. Lew, J.-B. Soerjomataram, I. and Canfell, K. (2019). Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. The Lancet Oncology, 20(3), 394-407. https://doi.org/10.1016/S1470-2045(18)30836-2.
- ACS (American Cancer Society) (2019). What is Cervical Cancer. Retrieved from https://www.cancer.org/cancer/cervical-cancer/about/what-is-cervical-cancer.html.
- ACS (American Cancer Society) (2020a). Early Detection, Diagnosis, and Staging.
- ACS (American Cancer Society) (2020b). Risk factors of cervical cancer. Retrieved from https://www.cancer.org/cancer/cervical-cancer/causes-risks-prevention/risk-factors.html.
- ACS (American Cancer Society) (2020c). Signs and Symptoms of Cervical Cancer. Retrieved from https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/signs-symptoms.html.
- Sung, H. Ferlay, J. Siegel, R. L. Laversanne, M. Soerjomataram, I. Jemal, A. and Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
- Sutcliffe, S. (2010). From cancer care to cancer control: organization of population-based cancer control systems. Cancer Control, 279.
- Taira, A. V. Neukermans, C. P. and Sanders, G. D. (2004). Evaluating human papillomavirus vaccination programs. Emerging infectious diseases, 10(11), 1915-1923.
- Waggoner, S. E. (2003). Cervical cancer. The Lancet, 361(9376), 2217-2225.
© 2021 The Authors. This article is freely available for anyone to read, share, download, print, permitted for unrestricted use and build upon, provided that the original author(s) and publisher are given due credit. All Published articles are distributed under the Creative Commons Attribution 4.0 International License.
Journal of Molecular Studies and Medicine Research EISSN 2414-5009.